相关实验视频

Updated: Jun 21, 2025

Systematic Approach to Identify Novel Antimicrobial and Antibiofilm Molecules from Plants' Extracts and Fractions to Prevent Dental Caries

Systematic Approach to Identify Novel Antimicrobial and Antibiofilm Molecules from Plants' Extracts and Fractions to Prevent Dental Caries

Published on: March 31, 2021

硫酸炭甲基纤维素/Azadirachta indica基于叶粉的生物复合材料的抗凝活动

Khalid A Alamry¹, Mahmoud A Hussein^1,2, Ajahar Khan^1,3

¹Faculty of Science, Department of Chemistry, King Abdulaziz University Jeddah 21589 Saudi Arabia kaalamri@kau.edu.sa maabdo@kau.edu.sa.

|July 15, 2024

概括

绿色合成的聚合物生物复合物来自硫酸碳甲基纤维素和阿扎迪拉赫塔印加叶粉具有有前途的抗凝活性. 这种环保材料显示出作为血液凝结管理的安全替代品的潜力.

科学领域:

材料科学材料科学材料科学
生物化学生物化学
药理学药理学是指药理学的学科.

背景情况:

通过绿色化学合成的聚合物生物复合材料具有环保和无毒的抗凝固特性.
将天然草药整合到生物复合材料中可以产生显著的治疗效益.

研究的目的:

开发一种新的混合生物复合材料,使用硫化碳甲基纤维素 (S-CMC) 和阿扎迪拉赫塔印加叶粉 (NLP).
评估合成的S-CMC/NLP生物复合材料的抗凝剂潜力.

主要方法:

使用无毒的硫化剂修改了碳氧甲基纤维素,以产生S-CMC.
制造的S-CMC/NLP生物复合材料具有不同的NLP度.
使用FE-SEM,EDX,XRD和FTIR光谱进行了结构性表征.
通过PT和APTT测定来评估抗凝剂活性.

主要成果:

在S-CMC/NLP生物复合物中,表现出与肝素相似的功能组 (COO-, -OH, SO3-).
在APTT试验中,2-NLP/S-CMC生物复合物证明了血液凝固时间的剂量依赖延长.
通过凝固系统的内在途径观察到抗凝固效应.

结论:

这种S-CMC/NLP生物复合材料具有具有抗凝性质的结构特征.
制造的生物复合材料显示出作为安全有效的抗凝剂的巨大潜力.
这项研究强调了开发新型抗凝固剂的绿色和可持续方法.

更多相关视频

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

Bacterial Cellulose Spheres that Encapsulate Solid Materials

Bacterial Cellulose Spheres that Encapsulate Solid Materials

Published on: February 26, 2021

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...